Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2012-11-26

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm301212uPMID 23072339PMCID PMC3967745
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential.

  2012cited by this paper
• Mutagenesis and computer modeling studies of a GPCR conserved residue W5.43(194) in ligand recognition and signal transduction for CB2 receptor.

  2011cited by this paper
• Brain Cannabinoid CB2 Receptors Modulate Cocaine’s Actions in Mice

  2011cited by this paper
• Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists.

  2011cited by this paper
• Cannabinoids and Bone: Friend or Foe?

  2010cited by this paper
• Recent Advances in Fragment-Based QSAR and Multi-Dimensional QSAR Methods

  2010cited by this paper
• Cannabinoid receptor ligands as potential anticancer agents--high hopes for new therapies?

  2009cited by this paper
• 6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction.

  2009cited by this paper
• Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects

  2008cited by this paper
• Regression of Fibrosis after Chronic Stimulation of Cannabinoid CB2 Receptor in Cirrhotic Rats

  2008cited by this paper
• Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review.

  2008cited by this paper
• KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling

  2008cited by this paper
• The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis.

  2008cited by this paper
• Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands

  2008cited by this paper
• Beta-caryophyllene is a dietary cannabinoid

  2008cited by this paper
• Data Mining a Small Molecule Drug Screening Representative Subset from NIH PubChem

  2008cited by this paper
• Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor.

  2008cited by this paper
• Role of Osteopathic Manipulative Treatment in Altering Pain Biomarkers: A Pilot Study

  2007cited by this paper
• Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.

  2007cited by this paper
• The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis

  2007cited by this paper
• Cannabinoid CB2 receptor: a new target for controlling neural cell survival?

  2007cited by this paper
• SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth.

  2007cited by this paper
• Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System

  2007cited by this paper
• GALAHAD Tripos, Inc., 1699 South Hanley Road, St. Louis, MO 63144-2319. www.tripos.com. Contact company for pricing information.

  2007cited by this paper
• The Endocannabinoid System as an Emerging Target of Pharmacotherapy

  2006cited by this paper
• A Novel Cannabinoid Peripheral Cannabinoid Receptor-Selective Inverse Agonist Blocks Leukocyte Recruitment in Vivo

  2006cited by this paper
• 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach.

  2006cited by this paper
• Targeting the cannabinoid CB2 receptor: mutations, modeling and development of CB2 selective ligands.

  2005cited by this paper
• Synthesis of enamides from aldehydes and amides

  2004cited by this paper
• 3D structural model of the G‐protein‐coupled cannabinoid CB2 receptor

  2003cited by this paper
• Cannabinergic ligands.

  2002cited by this paper
• Synthesis and Structure−Activity Relationships of Amide and Hydrazide Analogues of the Cannabinoid CB1 Receptor Antagonist N-(Piperidinyl)- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716)

  2002cited by this paper
• Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives.

  2002cited by this paper
• In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor.

  2001cited by this paper
• Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.

  2001cited by this paper
• Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor.

  2000cited by this paper
• Agonist‐inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630

  1999cited by this paper
• Cannabimimetic indoles, pyrroles and indenes.

  1999cited by this paper
• SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.

  1998cited by this paper
• Functional role of high-affinity anandamide transport, as revealed by selective inhibition.

  1997cited by this paper
• Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides

  1996cited by this paper
• The Conformational Properties of the Highly Selective Cannabinoid Receptor Ligand CP-55,940 (*)

  1996cited by this paper
• Molecular characterization of a peripheral receptor for cannabinoids

  1993cited by this paper
• Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.

  1993cited by this paper
• Structure of a cannabinoid receptor and functional expression of the cloned cDNA

  1990cited by this paper
• Themed Issue: Cannabinoids in Biology and Medicine, Part I the Endocannabinoid System and Cancer: Therapeutic Implication Received Revised Linked Articles

  year unknowncited by this paper

• GCN-BBB: Deep Learning Blood-Brain Barrier (BBB) Permeability PharmacoAnalytics with Graph Convolutional Neural (GCN) Network

  2025cites this paper
• Room temperature palladium-catalyzed synthesis of novel unsymmetrical diamide scaffolds containing moieties of α-ketoester as potential antibacterial, antifungal and anticancer agents

  2024cites this paper
• Study on indole CB2 ligands based on 3D-QSAR, molecular docking and molecular dynamics simulation

  2024cites this paper
• Cannabinoids: Role in Neurological Diseases and Psychiatric Disorders

  2024cites this paper
• A systematic review of novel cannabinoids and their targets: insights into the significance of structure in activity.

  2024cites this paper
• Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present)

  2024cites this paper
• Discovery of Potent and Selective CB2 Agonists Utilizing a Function-Based Computational Screening Protocol

  2023cites this paper
• Access to Functionalized Mannich Scaffolds via a Calcium Catalyzed Dehydrative Aza-Friedel-Crafts Reaction

  2023cites this paper
• Effect of N-phenylbenzenesulfonamide Targeting CNR2 over human bone marrow mesenchymal stem cell Population and Osteoblast/Adipocyte Differentiation

  2023cites this paper
• Artificial Intelligent Deep Learning Molecular Generative Modeling of Scaffold-Focused and Cannabinoid CB2 Target-Specific Small-Molecule Sublibraries

  2022cites this paper
• Rational drug design of CB2 receptor ligands: from 2012 to 2021

  2022cites this paper
• N-[1,3-Dialkyl(aryl)-2-oxoimidazolidin-4-ylidene]-aryl(alkyl)sulphonamides as Novel Selective Human Cannabinoid Type 2 Receptor (hCB2R) Ligands; Insights into the Mechanism of Receptor Activation/Deactivation

  2022cites this paper
• Investigating the Role of Natural Deep Eutectic Low Melting Mixtures for the Synthesis of Symmetrical Bisamides

  2021cites this paper
• Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010.

  2021cites this paper
• Efficient heterogeneous hydroaminocarbonylation of olefins with ammonium chloride as amino source

  2021cites this paper
• Biological activities of [1,2,4]triazolo[1,5-a]pyrimidines and analogs

  2020cites this paper
• Benzimidates as gem-Diamidation and Amidoindolyzation Cascade Synthons with a Hydrated NiII Catalyst.

  2020cites this paper
• The synthesis and structure of pyridine-oxadiazole iridium complexes and catalytic applications: Non-coordinating-anion-tuned selective C N bond formation

  2020cites this paper
• Cryo-EM Structure of the Human Cannabinoid Receptor CB2-Gi Signaling Complex.

  2020cites this paper
• Iridium Supported on Phosphorus‐Doped Porous Organic Polymers: Active and Recyclable Catalyst for Acceptorless Dehydrogenation and Borrowing Hydrogen Reaction

  2019cites this paper
• New Insights in Cannabinoid Receptor Structure and Signaling.

  2019cites this paper
• Prediction of Orthosteric and Allosteric Regulations on Cannabinoid Receptors Using Supervised Machine Learning Classifiers.

  2019cites this paper
• Development of novel oxazolo[5,4-d]pyrimidines as competitive CB2 neutral antagonists based on scaffold hopping.

  2018cites this paper
• A nano silver-xerogel (Ag nps@modified TEOS) as a newly developed nanocatalyst in the synthesis of benzopyranopyrimidines (with secondary and primary amines) and gem-bisamides.

  2017cites this paper
• p62/SQSTM1/Sequestosome-1 is an N-recognin of the N-end rule pathway which modulates autophagosome biogenesis

  2017cites this paper
• Design and synthesis of potent N-phenylpyrimidine derivatives for the treatment of skin cancer

  2016cites this paper
• Difference and Influence of Inactive and Active States of Cannabinoid Receptor Subtype CB2: From Conformation to Drug Discovery

  2016cites this paper
• Synthesis, molecular modeling and SAR study of novel pyrazolo[5,1-f][1,6]naphthyridines as CB2 receptor antagonists/inverse agonists.

  2016cites this paper
• Multi-Functional Diarylurea Small Molecule Inhibitors of TRPV1 with Therapeutic Potential for Neuroinflammation

  2016cites this paper
• Synthesis and structure activity relationship investigation of triazolo[1,5-a]pyrimidines as CB2 cannabinoid receptor inverse agonists.

  2016cites this paper
• Identification of novel PfDHODH inhibitors as antimalarial agents via pharmacophore-based virtual screening followed by molecular docking and in vivo antimalarial activity

  2016cites this paper
• In Silico Chemogenomics Knowledgebase and Computational System Neuropharmacology Approach for Cannabinoid Drug Research

  2016cites this paper
• Anion transport and binding properties of N N′-(phenylmethylene)dibenzamide based receptors

  2016cites this paper
• Synthesis of Bioorganometallic Nanomolar-Potent CB2 Agonists Containing a Ferrocene Unit

  2016cites this paper
• Discovery of (E)-3-(4-(Diethylamino) phenyl)-1-phenyl-2-phenylsulfonyl)prop-2-en-1-one as Novel Cannabinoid Receptor 2 Ligands

  2016influential citation
• Targeting cannabinoid receptor‐2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption

  2015influential citation
• Discovery of novel INK4C small-molecule inhibitors to promote human and murine hematopoietic stem cell ex vivo expansion

  2015cites this paper
• Synthesis, biological activity and molecular modeling of new biphenylic carboxamides as potent and selective CB2 receptor ligands.

  2015cites this paper
• Recent advances in antimultiple myeloma drug development.

  2014cites this paper
• Examining the critical roles of human CB2 receptor residues Valine 3.32 (113) and Leucine 5.41 (192) in ligand recognition and downstream signaling activities.

  2014cites this paper
• Modeling, Molecular Dynamics Simulation, and Mutation Validation for Structure of Cannabinoid Receptor 2 Based on Known Crystal Structures of GPCRs

  2014cites this paper
• TRPC1 is involved in Ca²⁺ influx and cytotoxicity following Pb²⁺ exposure in human embryonic kidney cells.

  2014cites this paper
• Latest progress in the identification of novel synthetic ligands for the cannabinoid CB2 receptor.

  2014cites this paper
• Design, synthesis, biological evaluation, and comparative docking study of 1,2,4-triazolones as CB1 receptor selective antagonists.

  2014cites this paper
• Trisubstituted Sulfonamides: a New Chemotype for Development of Potent and Selective CB2 Receptor Inverse Agonists.

  2013cites this paper
• Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation.

  2013cites this paper
• Recent development of CB2 selective and peripheral CB1/CB2 cannabinoid receptor ligands.

  2013cites this paper
• A convenient synthesis of bisamides with BF3 etherate as catalyst

  2013cites this paper
• LiCABEDS II. Modeling of Ligand Selectivity for G-Protein-Coupled Cannabinoid Receptors

  2013cites this paper